Intuitive Surgical -- How the Business Works

Intuitive Surgical operates the definitive razor-and-blade business model in robotic surgery. The company places da Vinci and Ion systems (the razors) in hospitals, then generates recurring revenue from instruments and accessories (I&A) consumed during every procedure and service contracts that maintain the installed base. In FY2025, recurring revenue from I&A and Services represented ~81% of total revenue -- meaning for every system sold, Intuitive captures decades of high-margin consumables and services. With 11,106 da Vinci systems and 995 Ion systems installed globally, the flywheel is self-reinforcing: more systems placed means more surgeons trained, more procedures performed, more I&A consumed, and more data generated to improve AI-driven surgical outcomes.
FY2025 Revenue
$10.1B
+20.5% YoY
Instruments and Accessories
$6.0B
~60% of revenue
Systems
$2.5B
~25% of revenue
Services
$1.6B
~16% of revenue
The razor-and-blade model -- systems drive recurring revenue
Razor / Blade Economics -- FY2025
THE RAZOR -- System Placements
$2.5B  (~19% of revenue)
1,721 da Vinci systems placed in FY2025 (+12.8% YoY). System ASP ~$1.5-1.7M depending on configuration. Includes da Vinci 5 (870 placements), da Vinci Xi, and XiR refurbished units. Each placement seeds a multi-decade revenue stream from consumables and services.
One-time capital sale
▶
THE BLADES -- Recurring Revenue (81% of total)
$7.6B  (I&A $6.0B + Services $1.6B)
Every procedure consumes single-use instruments, accessories, and drapes. Each da Vinci system generates ~$200K+ per year in recurring I&A and service revenue. With 11,106 systems installed, the recurring base compounds automatically as procedure volumes grow 17-18% annually. Service contracts provide maintenance, software updates, and technical support.
Recurring, high-margin, procedure-driven
System Price
~$1.5-1.7M
One-time
Annual Recurring / System
~$200K+
I&A + Services
Installed Base (Da Vinci)
11,106
+12.2% YoY
System Lifetime Value
~$2M+
Over 10+ year life
Revenue breakdown from ISRG FY2025 10-K and earnings supplement. Source: Daloopa.
Revenue breakdown -- FY2025 ($10.1B total)
FY2025 Revenue by Stream -- Ranked by Size
Instruments and Accessories
Consumable instruments, stapler reloads, accessories, drapes
$6.0B  (60%)
Systems
Da Vinci 5, Xi, XiR, Ion system sales and leases
$2.5B  (25%)
Services
Service contracts, training, maintenance, software updates
$1.6B  (16%)
Segment data from ISRG FY2025 earnings supplement. Source: Daloopa.
The installed base flywheel -- self-reinforcing growth
Flywheel Dynamics -- Each Step Reinforces the Next
Step 1 -- Place Systems in Hospitals
11,106 Da Vinci + 995 Ion Systems Installed Globally
Intuitive places robotic systems in hospitals worldwide. 1,721 da Vinci systems placed in FY2025 (+12.8% YoY). The da Vinci 5 launch drove 870 placements of the new platform. Each placement creates a long-duration annuity stream -- hospitals commit to a platform that integrates deeply into surgical workflows, OR scheduling, and training programs.
▼
Step 2 -- Train Surgeons on the Platform
50,000+ Trained Surgeons Worldwide -- High Switching Costs
Surgeons invest significant time learning da Vinci (simulation, proctored cases, skill building). Once trained, they prefer to operate on the platform they know -- creating powerful lock-in. 10,000+ surgeons already trained on da Vinci 5 alone. Hospitals that train their surgical staff on Intuitive systems are unlikely to switch to a competitor, especially when clinical data validates better outcomes.
▼
Step 3 -- Procedures Generate I&A Revenue
18% Da Vinci Procedure Growth in FY2025 -- $6.0B in I&A Revenue
Every robotic procedure consumes single-use instruments, accessories, and drapes. Procedure growth of 18% globally in FY2025 drove I&A revenue to $6.0B (+18.5% YoY). Each system generates ~$200K+ per year in recurring revenue. The more procedures performed, the more consumables consumed -- and procedure volumes compound as surgeons expand into new specialties and geographies.
▼
Step 4 -- Surgical Data Improves AI and Outcomes
20M+ Cumulative Procedures -- Largest Surgical Dataset in the World
Every procedure generates data that feeds into Case Insights, AI-powered surgical analytics, and real-time 3D model overlays on da Vinci 5 (with 10,000x more computing power than Xi). The MIA+ digital subscription platform provides simulation, telepresence, and AI-driven insights. No competitor can replicate 20+ years of surgical data from millions of procedures. This data moat widens with every case performed.
▼
Step 5 -- More Hospitals Adopt → Flywheel Accelerates
9M+ Addressable Procedures -- OUS Growth 23% -- ASC Expansion Begins
Better outcomes attract more hospitals to adopt. International procedure growth of 23% YoY and general surgery penetration expanding. ASCs opening with XiR refurbished systems at lower price points. Addressable procedures grew from 7M (2024) to 9M+ (2026) as clinical validation broadens into benign procedures, cardiac surgery, and lung biopsy (Ion). Each new hospital placed restarts the flywheel from Step 1.
↻ Flywheel loops back to Step 1 -- each cycle compounds the installed base
Flywheel data from ISRG FY2025 earnings calls, investor presentations, and 10-K filing.
Product portfolio -- four platforms serving distinct markets
Platform Portfolio -- FY2025
Da Vinci 5 Next-generation flagship
870 placements in FY2025. Force Feedback (55% reduction in tissue force), 10,000x computing power, Case Insights AI analytics, real-time 3D overlay. MIA+ digital subscription for simulation and telepresence. 10,000+ surgeons trained. Broadest procedure clearance portfolio.
Da Vinci Xi Workhorse platform
The current installed base backbone with 11,106 total da Vinci systems. Multi-quadrant access, fluorescence imaging, integrated table motion. Proven across urology, gynecology, general surgery, thoracic, and head/neck procedures. Being upgraded to dV5 through trade-in programs.
Da Vinci XiR Refurbished Xi for expansion
Trade-ins from dV5 upgrades create refurbished Xi inventory at lower price points. Targets ambulatory surgery centers (ASCs) and international greenfield markets. 42 XiR placements in FY2025. ~70% of ASC opportunity is within existing hospital networks where surgeons are already trained.
Ion Lung biopsy platform
Robotic-assisted bronchoscopy for minimally invasive lung biopsy. 995 systems installed (+23.6% YoY). 40,200 procedures in Q4 2025 alone. Approaching halfway penetration of US bronchoscopic biopsy market. Early launches in Europe, Korea, China, and Australia. Growing TAM as lung cancer screening expands.
Product data from ISRG FY2025 earnings calls, FDA clearance announcements, and investor presentations.
Revenue stream deep dive -- how each stream works

Instruments and Accessories ($6.0B, ~60% of revenue, +18.5% YoY). The core of the business model. Every da Vinci procedure requires single-use instruments (EndoWrist instruments with limited-use counters), stapler reloads, accessories, and sterile drapes. Instruments are procedure-specific and designed to be replaced after a set number of uses, ensuring per-procedure revenue capture. I&A revenue grows as a function of two variables: installed base size (11,106 da Vinci systems, +12.2% YoY) and utilization per system (procedure growth of 18% exceeded base growth, indicating rising utilization). The da Vinci 5 introduces Force Feedback instruments at premium pricing, which should drive higher I&A per procedure over time. FY2025 I&A revenue of $6.0B grew faster than procedure growth, reflecting favorable mix toward higher-value instruments.

Systems ($2.5B, ~25% of revenue, +25.9% YoY). Capital equipment revenue from selling and leasing da Vinci and Ion systems. FY2025 was a strong placement year with 1,721 da Vinci systems (+12.8% YoY), driven by the da Vinci 5 launch cycle (870 dV5 placements). System ASPs ranged from $1.38M to $1.68M per quarter, trending higher as dV5 commands premium pricing. The trade-in cycle from Xi to dV5 generates higher initial revenue but also produces XiR refurbished inventory for secondary market expansion. Leasing penetration is growing, which converts some upfront system revenue into recurring lease payments. While systems are the smallest revenue stream, they are the critical entry point that seeds the much larger recurring I&A and services annuity.

Services ($1.6B, ~16% of revenue, +20.1% YoY). Service contracts covering maintenance, repairs, software updates, and technical support for the installed base. Revenue grows in near-lockstep with installed base expansion. Service contracts are typically multi-year agreements with high renewal rates -- once a hospital depends on robotic surgery for daily case volumes, maintaining system uptime is non-negotiable. FY2025 services revenue of $1.6B grew 20.1% YoY, roughly matching installed base growth plus pricing escalators. As the dV5 platform matures, MIA+ digital subscriptions (simulation, telepresence, Case Insights) represent a new layer of recurring service revenue with renewals beginning mid-2026. This could expand the services stream beyond traditional hardware maintenance into higher-margin software and data services.

Data sourced from Daloopa, ISRG 10-K/10-Q filings, and earnings transcripts.